“Transparency is one of the keys to market-based reforms that will lead to lower prices and ensure that taxpayers receive a real return on their investment." Read More
CSRxP has launched a national campaign as part of a multi-million-dollar effort to hold Big Pharma accountable for their out-of-control prescription drug prices. Because Big Pharma blocks competition to maintain monopolies on medicines, they can set any price they want. Read More
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety." Read More
"The FAST Generics Act represents market-based reforms that will increase competition and ensure that lifesaving medications can safely reach patients at an affordable price." Read More
American Academy of Family Physicians Joins CSRxP The Campaign for Sustainable… Read More
"We must ‘bring down the artificially high price of drugs and bring them down immediately.’ That’s what the President said in his address to Congress – and the American people agree. Read More
We applaud President Trump for making the out-of-control prices of prescription drugs a priority in his Administration. Read More
"No amount of advertising will make hardworking families forget the consequences of their out-of-control drug costs." Read More
A new HHS Office of the Inspector General report finds that high-priced prescription drugs are threatening the sustainability of the taxpayer-funded Medicare Part D program. Read More
The drug industry is front and center in a national dialogue. How do we make sure patients around the world can get the medicines they need? Can we balance costs and the need for innovation? Pharma leaders answer Forbes’ questions – and yours. Read More
"We are encouraged to see the president-elect is ready to take action. We look forward to working with the new Administration and the new Congress to find solutions to fix the broken prescription drug market, and to help make life-saving medications more affordable for the patients who need them.” Read More
Based on Novo Nordisk’s announcement, it is clear that the company will continue to hike insulin prices, despite the financial burdens already facing patients. “The prescription drug market is clearly broken when limiting yearly price increases to ten percent is considered bighearted,” said John Rother. Read More